Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07600762 | A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants | PHASE1 | NOT YET_RECRUITING | 12 | — | — | Apr 25, 2026 | Jun 1, 2026 | May 26, 2026 | 1 | United States |
Cmax of Nacresertib
Tmax of Nacresertib
AUCt of Nacresertib
AUCinf of Nacresertib
Beta of Nacresertib
t1/2 of Nacresertib
Any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment
| Arm | Type | Description |
|---|---|---|
| Nacresertib | EXPERIMENTAL | Participants will receive a single dose of Nacresertib |
| Placebo for Nacresertib | PLACEBO_COMPARATOR | Participants will receive a single dose of Placebo for Nacresertib |
| Name | Type | Description |
|---|---|---|
| Nacresertib | DRUG | Oral tablet |
| Placebo for Nacresertib | DRUG | Oral tablet |
Inclusion Criteria: * Healthy Japanese male or female; 18 to 65 years of age at the time of screening. * Japanese participant must be first-or second-generation Japanese of full Japanese parentage. First-generation participants will have been born in Japan to two parents and four grandparents also ...